ZA201304235B - Oprf/i agents and their use in hospitalized and other patients - Google Patents

Oprf/i agents and their use in hospitalized and other patients

Info

Publication number
ZA201304235B
ZA201304235B ZA2013/04235A ZA201304235A ZA201304235B ZA 201304235 B ZA201304235 B ZA 201304235B ZA 2013/04235 A ZA2013/04235 A ZA 2013/04235A ZA 201304235 A ZA201304235 A ZA 201304235A ZA 201304235 B ZA201304235 B ZA 201304235B
Authority
ZA
South Africa
Prior art keywords
oprf
hospitalized
patients
agents
Prior art date
Application number
ZA2013/04235A
Other languages
English (en)
Inventor
Christoph Klade
Robert Schlegl
Kerstin Westritschnig
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of ZA201304235B publication Critical patent/ZA201304235B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2013/04235A 2010-12-23 2013-06-10 Oprf/i agents and their use in hospitalized and other patients ZA201304235B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061426760P 2010-12-23 2010-12-23
PCT/EP2011/054127 WO2012084272A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Publications (1)

Publication Number Publication Date
ZA201304235B true ZA201304235B (en) 2014-09-25

Family

ID=44210049

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/04235A ZA201304235B (en) 2010-12-23 2013-06-10 Oprf/i agents and their use in hospitalized and other patients

Country Status (11)

Country Link
US (1) US20130266575A1 (enExample)
EP (1) EP2655402A1 (enExample)
JP (2) JP5893640B2 (enExample)
KR (1) KR20130133212A (enExample)
CN (1) CN103270047A (enExample)
AU (1) AU2011348396A1 (enExample)
BR (1) BR112013016254A2 (enExample)
CA (1) CA2822684A1 (enExample)
MX (1) MX2013007146A (enExample)
WO (1) WO2012084272A1 (enExample)
ZA (1) ZA201304235B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
EP3185897A4 (en) * 2014-08-29 2018-05-02 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and opri
CN107922482A (zh) 2015-05-01 2018-04-17 英伊布里克斯有限合伙公司 Iii型分泌系统靶向分子
WO2016193402A1 (en) 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
CN114106178A (zh) 2015-07-16 2022-03-01 印希比股份有限公司 多价和多特异性结合dr5的融合蛋白
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494672A (en) * 1989-04-28 1996-02-27 S.P.I. Synthetic Peptides Incorporated Pseudomonas peptide composition and method
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
EP0717106B1 (en) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US20040197341A1 (en) * 2001-09-03 2004-10-07 Jean-Claude Pechere Therapeutic process for p. aeruginosa infections using macrolide antibiotics
AU2002340683C1 (en) * 2001-11-13 2009-11-12 Id Biomedical Corporation Of Quebec Polypeptides of pseudomonas aeruginosa
KR101399678B1 (ko) * 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
CN101076342A (zh) * 2004-12-17 2007-11-21 维纳斯药业有限公司 用于对治疗感染提供总解决方案的抗生素组合
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
US9987344B2 (en) * 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations

Also Published As

Publication number Publication date
AU2011348396A1 (en) 2013-07-04
EP2655402A1 (en) 2013-10-30
CA2822684A1 (en) 2012-06-28
CN103270047A (zh) 2013-08-28
US20130266575A1 (en) 2013-10-10
JP2016147867A (ja) 2016-08-18
BR112013016254A2 (pt) 2017-07-11
JP5893640B2 (ja) 2016-03-23
KR20130133212A (ko) 2013-12-06
WO2012084272A1 (en) 2012-06-28
MX2013007146A (es) 2013-11-01
AU2011348396A2 (en) 2013-07-11
JP2014504297A (ja) 2014-02-20

Similar Documents

Publication Publication Date Title
IL221511A (en) Arilatriazolones associated with bis aryl and their use
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
ZA201208173B (en) Peptices and their use
PT2592933T (pt) Inibidores de mif e suas utilizações
ZA201208948B (en) Modified beta-lactamases and methods and uses related thereto
ZA201303773B (en) Compounds and their use
EP2563131A4 (en) PESTICIDAL COMPOSITION AND USE THEREOF
PT2521445T (pt) Formulação e utilização da mesma
ZA201207242B (en) Pesticidal composition and its use
PL2563133T3 (pl) Kompozycja szkodnikobójcza i jej zastosowanie
BR112013016254A2 (pt) agentes oprf/i e seu uso em pacientes hospitalizados e outros
GB0920258D0 (en) New medical agents and use thereof
PL2552440T3 (pl) Nowa kombinacja i zastosowanie
PL2563134T3 (pl) Kompozycja szkodnikobójcza i jej zastosowanie
PL2648715T3 (pl) Mieszaniny karnozyny-kwasu hialuronowego i ich zastosowanie
PT2563806E (pt) Leucolectinas humanas e suas utilizações
GB201017820D0 (en) Cells and devices
GB201008286D0 (en) Device and use
HK1191024A (en) Oprf/i agents and their use in hospitalized and other patients
GB201005826D0 (en) New compositions and their use
AU335567S (en) Combination patient education and storage article
GB201018028D0 (en) Compounds and their use
GB201000307D0 (en) Compounds and their use
GB201020848D0 (en) Compounds and their use
GB201005511D0 (en) Compounds and their use